Engineered TCRs Targeting HPV E6 Antigens

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for HPV-associated cancers, such as cervical cancer, have limited efficacy, necessitating the development of more effective therapies.

Innovation Solution

Genetically engineered T cells expressing a T cell receptor (TCR) specific to the HPV E6 antigen, combined with a checkpoint inhibitor, are introduced to recognize and target cancer cells expressing HPV E6, stimulating cytotoxic activity against these cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (chemotherapy) are used for HPV-associated cancers, then treatment can be administered, but the efficacy is relatively poor

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtreatment effectiveness

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent introduces engineered T cells as an intermediary between the patient's immune system and the cancer cells. These T cells are genetically modified to express TCRs that specifically recognize HPV E6 antigen, acting as a bridge to enable targeted immune attack on cancer cells while sparing healthy tissue, thereby improving treatment efficacy compared to conventional chemotherapy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the fundamental parameter of treatment approach from non-specific chemotherapy to specific immunotherapy. By modifying the T cells' antigen recognition parameters through genetic engineering to target HPV E6 specifically, the treatment achieves higher efficacy with reduced off-target effects compared to conventional approaches

Inventive Principle:

Principle #35Parameter changes

2Reliability

If T cells are engineered to recognize HPV E6 antigen, then specific cytotoxic activity is stimulated, but the treatment complexity increases

Engineering Contradiction:

Improvetargeted cytotoxic activityVSAvoidcell engineering complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the treatment approach into distinct functional modules: (1) T cell isolation from patient, (2) genetic modification to express specific TCR against HPV E6, (3) expansion of engineered cells, and (4) reinfusion. This segmentation allows each step to be optimized independently while maintaining overall treatment efficacy

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a universal platform for treating HPV-associated cancers by engineering T cells with TCRs specific to the conserved HPV E6 antigen. This approach can be applied across different HPV-associated cancer types (cervical, head and neck, anal cancers), providing a multi-functional solution that addresses multiple indications with a single engineered cell product

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The engineered T cells effectively recognize and kill HPV E6-positive cancer cells, potentially leading to improved treatment outcomes for HPV-associated cancers by enhancing immune response and reducing tumor burden.

Implementation Method 1

T cell receptor (TCR) that specifically binds to an antigen of human papilloma virus (HPV)

Methodology Applied

Scientific EffectAntigen recognition and binding:

Implementation Method 2

stimulating cytotoxic activity against these cells

Methodology Applied

Scientific EffectCytotoxic activity:

Data Source

PatentUS20230077100A1Anti-HPV t cell receptors and engineered cells

Publication Date: 2023.03.09 GUANGDONG TCRCURE BIOPHARMA TECH CO LTD

AI summary

T cell receptors that recognize or bind to human papilloma virus (HPV) antigens, genetically engineered cells and cell-based therapies are provided.